Title: NHS Psilocybin for Depression: A Divisive Medical Frontier

Larissa Hope contends that psilocybin, the psychoactive compound found in magic mushrooms, was instrumental in helping her navigate a severe mental health crisis. The actress, who rose to prominence at age 17 with a role in the television series Skins, found that the sudden attention triggered latent trauma. While conventional antidepressants proved ineffective for her, a clinically supervised dose of psilocybin marked a pivotal shift in her recovery. “When I experienced it, I burst out crying,” Hope recalls. “It was the first time in my life I had ever felt a sense of belonging and safety in my body. I kept saying, ‘I’m home, I’m home.’” Nearly two decades later, Hope credits this experience, combined with therapeutic support, as crucial in helping her overcome suicidal ideation.

However, not all accounts are so positive. Jules Evans, a university researcher, had a profoundly negative reaction to LSD, which he used recreationally at the age of 18. The experience plunged him into what he describes as a “deluded” state. “I believed that everyone was talking about me, criticising me, judging me. I thought, I’ve permanently damaged myself; I’ve permanently lost my mind,” he says. Evans now leads the Challenging Psychedelic Experiences Project, an initiative designed to support individuals suffering adverse effects from psychedelics. He notes that years after his initial trip, he continued to struggle with social anxiety and panic attacks, eventually receiving a diagnosis of post-traumatic stress disorder (PTSD).

These contrasting narratives underscore the central dilemma currently confronting clinicians, regulators, and policymakers: should physicians be permitted to prescribe treatments involving magic mushrooms and other potentially therapeutic psychedelic substances?

This question has gained urgency following a wave of recent studies indicating that psychedelic drugs may offer relief for depression, obsessive-compulsive disorder (OCD), PTSD, trauma, and addictions ranging from alcohol to gambling. Currently, the use of psychedelic medicine remains prohibited except within authorized clinical trials or research settings. Since 2022, over 20 trials have investigated various psychedelic compounds for conditions including depression and addiction. While numerous studies suggest therapeutic benefits, others have yielded ambiguous or mixed outcomes, with only a small minority finding no significant improvement on primary metrics.

The UK’s medicines regulator is currently awaiting data from one of the largest psilocybin clinical trials, conducted by biotech firm Compass Pathways, expected later this year. This data will inform the regulator’s decision on whether to loosen current stringent restrictions and permit the use of these medicines outside of research frameworks.

Prof Oliver Howes, chair of the Royal College of Psychiatrists’ Psychopharmacology Committee, expresses optimism regarding the potential of these treatments within the NHS. He views psychedelics as a promising new avenue for psychiatric care, particularly given the urgent need for improved mental health interventions. “One of the key messages is that this is something we desperately need – more treatments and better treatments for mental health disorders,” Howes states. He highlights that while early small-scale studies show promise, these treatments could potentially act more rapidly than existing options. Nevertheless, he urges caution, stressing the importance of robust evidence over exaggerated expectations. “It’s really important that we get evidence and not overhype the potential benefits.”

Other experts have echoed calls for prudence. A September 2025 report from the Royal College of Psychiatrists cautioned against the potential risks associated with psychedelics. Furthermore, medical professionals emphasize that beyond being illegal, the recreational use of psychedelic drugs can be physically and psychologically harmful.

The history of drug use is as ancient as civilization itself, with substances like magic mushrooms, opium, and cannabis long utilized for both ritualistic and recreational purposes. By the 1960s and 1970s, LSD, also...

Source: BBC News Generated at: 2026-01-02 15:47:15 UTC